Corbus Pharmaceuticals Holdings (3371) Stock Overview

A clinical stage company, develops and commercializes therapeutics for cancer and obesity. More details

3371 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 77.2% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been substantially diluted in the past year

+ 1 more risk

3371 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW472,568 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

472,568 investors already sharing narratives

View all narratives

Corbus Pharmaceuticals Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Corbus Pharmaceuticals Holdings
Historical stock prices
Current Share Price	US$8.40
52 Week High	US$18.40
52 Week Low	US$5.80
Beta	2.62
1 Month Change	10.10%
3 Month Change	-15.71%
1 Year Change	9.03%
3 Year Change	n/a
5 Year Change	-71.68%
Change since IPO	-89.44%

Recent updates

Shareholder Returns

	3371	DE Biotechs	DE Market
7D	4.8%	-0.3%	0.3%
1Y	9.0%	7.6%	3.0%

Return vs Industry: 3371 exceeded the German Biotechs industry which returned 7% over the past year.

Return vs Market: 3371 exceeded the German Market which returned 3.6% over the past year.

Price Volatility

Is 3371's price volatile compared to industry and market?
3371 volatility
3371 Average Weekly Movement	14.7%
Biotechs Industry Average Movement	6.5%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 3371's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3371's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2009	36	Yuval Cohen	www.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary

How do Corbus Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
3371 fundamental statistics
Market cap	€163.74m
Earnings (TTM)	-€88.39m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Is 3371 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3371 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$90.26m
Gross Profit	-US$90.26m
Other Expenses	US$11.64m
Earnings	-US$101.90m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-5.27
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 3371 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/13 20:06
End of Day Share Price	2026/08/13 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kalpit Patel	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.

Corbus Pharmaceuticals Holdings (3371) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Corbus Pharmaceuticals Holdings, Inc. Competitors

Dextech Medical

Formycon

Novogenia

2invest

Price History & Performance

Recent News & Updates

New major risk - Financial position

Corbus Pharmaceuticals Announces FDA Clearance to Initiate Tempo-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

Recent updates

New major risk - Financial position

Corbus Pharmaceuticals Announces FDA Clearance to Initiate Tempo-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Corbus Pharmaceuticals Holdings, Inc. Announces Updated Clinical Data for CRB-701 At ASCO 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Chief Medical Officer Dr. Dominic Smethurst, Effective June 30, 2026

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 13, 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025

Corbus Pharmaceuticals Holdings, Inc. Reports Results from Phase 1A Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $74.999901 million.

Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025

Corbus Pharmaceuticals Holdings, Inc. to Host In-Person and Virtual KOL Event At ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB -701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Its Nectin-4 Targeting Adc CRB -701 At the 2025 ESMO Annual Congress

Corbus Pharmaceuticals Holdings Inc. Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell 3000E Value Index

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed with Its Nectin-4 Targeting ADC CRB-701 in Combination with Keytruda (Pembrolizumab)

Corbus Pharmaceuticals Holdings, Inc. Announces Board Changes, Effective May 15, 2025

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 15, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Peter Salzmann Not to Stand for Re-Election as Director of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Appoints Ian Hodgson as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021)

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)